Regulatory and conventional CD4+ T cells show differential effects correlating with PD-1 and B7-H1 expression after immunotherapy

Journal of Immunology

Volumn 180, Issue 5, 2008, Pages 2981-2988

  Alderson, Kory L ^a   Zhou, Qing ^a   Berner, Vanessa ^a   Wilkins, Danice E C ^a   Weiss, Jonathan M ^b   Blazar, Bruce R ^c   Welniak, Lisbeth A ^a   Wiltrout, Robert H ^b   Redelman, Doug ^a   Murphy, William J ^a,d  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF NEVADA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD40 ANTIBODY; CELL SURFACE MARKER; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 PROTEIN; PROTEIN B7 H1; RECOMBINANT INTERLEUKIN 15; RECOMBINANT INTERLEUKIN 2; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; ANTIBODY; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; B7 ANTIGEN; CD40 ANTIGEN; INTERLEUKIN 2; MEMBRANE ANTIGEN; MEMBRANE PROTEIN; PDCD1 PROTEIN, MOUSE; PDCD1LG1 PROTEIN, MOUSE; PEPTIDE; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELL EXPANSION; CELL LOSS; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEMATOPOIETIC CELL; KNOCKOUT GENE; LYMPHOCYTE COUNT; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; COMPARATIVE STUDY; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; MOUSE MUTANT; RAT;

ANIMALS; ANTIBODIES; ANTIGENS, CD40; ANTIGENS, CD80; ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDES; RATS; RECOMBINANT PROTEINS; T-LYMPHOCYTES, REGULATORY;

EID: 49149103178     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.5.2981     Document Type: Article

References (36)

1. + cell responses. J. Immunol. 170: 2727-2733.
2. + T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat. Med. 13: 354-360.
3. Bartholdy, C., S. O. Kauffmann, J. P. Christensen, and A. R. Thomsen. 2007. Agonistic anti-CD40 antibody profoundly suppresses the immune response to infection with lymphocytic choriomeningitis virus. J. Immunol. 178: 1662-1670.
4. Perez-Diez, A., N. T. Joncker, K. Choi, W. F. Chan, C. C. Anderson, O. Lantz, and P. Matzinger. 2007. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 109: 5346-5354.
5. Afzali, B., G. Lombardi, R. I. Lechler, and G. M. Lord. 2007. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin. Exp. Immunol. 148: 32-46.
6. Curiel, T. J. 2007. Tregs and rethinking cancer immunotherapy. J. Clin. Invest. 117: 1167-1174.
7. Ishida, Y., Y. Agata, K. Shibahara, and T. Honjo. 1992. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11: 3887-3895.
8. Okazaki, T., Y. Iwai, and T. Honjo. 2002. New regulatory co-receptors: inducible co-stimulator and PD-1. Curr. Opin. Immunol. 14: 779-782.
9. + T cell tolerance to tissue antigens. J. Immunol. 177: 8291-8295.
10. Keir, M. E., S. C. Liang, I. Guleria, Y. E. Latchman, A. Qipo, L. A. Albacker, M. Koulmanda, G. J. Freeman, M. H. Sayegh, and A. H. Sharpe. 2006. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. 203: 883-895.
11. Goldberg, M. V., C. H. Maris, E. L. Hipkiss, A. S. Flies, L. Zhen, R. M. Tuder, J. F. Grosso, T. J. Harris, D. Getnet, K. A. Whartenby, et al. 2007. Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood 110: 186-192.
12. Flies, D. B., and L. Chen. 2007. The new B7s: playing a pivotal role in tumor immunity. J. Immunother. 30: 251-260.
13. Freeman, G. J., A. J. Long, Y. Iwai, K. Bourque, T. Chernova, H. Nishimura, L. J. Fitz, N. Malenkovich, T. Okazaki, M. C. Byrne, et al. 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192: 1027-1034.
14. + regulatory T-cell selection. Immunol. Rev. 212: 74-85.
15. + regulatory T cells. Proc. Natl. Acad. Sci. USA 103: 5460-5465.
16. + T regulatory cells, immunotherapy of cancer, and interleukin-2. J. Immunother. 28: 120-128.
17. + memory T cells are IL-15 dependent. J. Exp. Med. 204: 951-961.
18. + T cell homeostasis. J. Exp. Med. 200: 825-834.
19. Sato, N., H. J. Patel, T. A. Waldmann, and Y. Tagaya. 2007. The IL-15/IL-15Rα on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells. Proc. Natl. Acad. Sci. USA 104: 588-593.
20. Shedlock, D. J., and H. Shen. 2003. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300: 337-339.
21. Sun, J. C., and M. J. Bevan. 2003. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300: 339-342.
22. + T-cell memory via TRAIL-mediated activation-induced cell death. Nature 434: 88-93.
23. Badovinac, V. P., K. A. Messingham, T. S. Griffith, and J. T. Harty. 2006. TRAIL deficiency delays, but does not prevent, erosion in the quality of "helpless" memory CD8 T cells. J. Immunol. 177: 999-1006.
24. + T cells in Hodgkin's lymphoma. Blood 110: 3226-3233.
25. + T cells in schistosomiasis correlate with morbidity. Parasite Immunol. 27: 45-53.
26. + T cells accumulate as unique anergic cells in rheumatoid arthritis synovial fluid. J. Rheumatol. 30: 1410-1419.
27. + T-cell exhaustion in typical progressors but not in long-term nonprogressors. Blood 109: 4671-4678.
28. Dong, H., S. E. Strome, D. R. Salomao, H. Tamura, F. Hirano, D. B. Flies, P. C. Roche, J. Lu, G. Zhu, K. Tamada, et al. 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8: 793-800.
29. Keir, M. E., L. M. Francisco, and A. H. Sharpe. 2007. PD-1 and its ligands in T-cell immunity. Curr. Opin. Immunol. 19: 309-314.
30. Grakoui, A., E. John Wherry, H. L. Hanson, C. Walker, and R. Ahmed. 2006. Turning on the off switch: regulation of anti-viral T cell responses in the liver by the PD-1/PD-L1 pathway. J. Hepatol. 45: 468-472.
31. Khoury, S. J., and M. H. Sayegh. 2004. The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. Immunity 20: 529-538.
32. Blazar, B. R., B. M. Carreno, A. Panoskaltsis-Mortari, L. Carter, Y. Iwai, H. Yagita, H. Nishimura, and P. A. Taylor. 2003. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-γ-dependent mechanism. J. Immunol. 171: 1272-1277.
33. Hori, J., M. Wang, M. Miyashita, K. Tanemoto, H. Takahashi, T. Takemori, K. Okumura, H. Yagita, and M. Azuma. 2006. B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts. J. Immunol. 177: 5928-5935.
34. + regulatory T cells. Infect. Immun. 75: 4334-4341.
35. Tsushima, F., S. Yao, T. Shin, A. Flies, S. Flies, H. Xu, K. Tamada, D. M. Pardoll, and L. Chen. 2007. Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood 110: 180-185.
36. Maker, A. V., P. Attia, and S. A. Rosenberg. 2005. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J. Immunol. 175: 7746-7754.